globe Menu Search

Fluid Air, a division of Spraying Systems Co., Signs Strategic Agreement with Sinopep Biotech to Revolutionize Peptide and Oligonucleotide Production


This joint effort aims to integrate Fluid Air's groundbreaking electrostatic drying technology into Sinopep's commercial production processes for peptides and oligonucleotides.

9

Jan 25



Fluid Air, a division of Spraying Systems Co., is excited to announce a strategic collaboration with Sinopep Biotech. This joint effort aims to integrate Fluid Air's groundbreaking electrostatic drying technology into Sinopep's commercial production processes for peptides and oligonucleotides. The contract was formally signed at Sinopep’s headquarters in Hangzhou, China, marking a significant milestone for both companies.

Founded in 1983, Fluid Air serves companies that manufacture powdered products and ingredients, in industries including biopharmaceutical, advanced batteries, nutraceutical, food, fine chemicals, and agriculture. This collaboration is aligned with Fluid Air’s ongoing mission to provide innovative solutions that enhance manufacturing processes in a variety of industries. The agreement was signed by Mr. Keith Cronce, Chief Operating Officer of Fluid Air, and Mr. Tong Ziquan, Chairman of Sinopep Biotech.

Sinopep Biotech has long been at the forefront of applying innovative technologies to the production of peptide and oligonucleotide raw materials. By introducing advanced spray drying techniques, Sinopep has solved critical challenges related to particle size distribution and created enhanced formulations for applications such as solid oral preparations, controlled-release drugs, and inhalation therapies. These developments have significantly improved the bioavailability of difficult-to-administer drugs while also addressing limitations in traditional production methods, such as condensation and freeze-drying processes, thus increasing overall production efficiency.

At the heart of this collaboration is Fluid Air’s patented PolarDry® technology—an innovative electrostatic drying solution that offers low drying temperatures and superior efficiency compared to conventional methods. This technology is poised to revolutionize peptide and oligonucleotide production in the same way freeze-drying and high-temperature spray drying once did, with key benefits including:

1.  Low-temperature, high-efficiency drying that preserves product quality and biological activity.
2. The ability to eliminate production bottlenecks, reducing cycle times and significantly improving overall production efficiency.

In this collaboration, Fluid Air’s PolarDry® technology is expected to transform peptide and oligonucleotide production by enabling stable, small-particle, spherical powder production. This advancement enhances material flow and uniformity in the preparation of drugs, addressing limitations in traditional processes such as rotary evaporation concentration and lyophilization. By reducing production cycles, the new technology is set to facilitate large-scale commercial manufacturing of high-quality peptides and oligonucleotides.

Sinopep Biotech has always placed innovation at the core of its business, consistently pushing the boundaries in the development of small molecules, peptides, and oligonucleotides. This collaboration with Fluid Air represents a significant step forward in Sinopep’s strategy to solidify its leadership position in the pharmaceutical industry. As a result, Sinopep Biotech is poised to expand its technological and competitive advantages, ensuring continued success in the global market for peptide and oligonucleotide manufacturing. This strategic collaboration with Fluid Air marks a new chapter in Sinopep’s growth, contributing to the accelerated development of the company and making a significant impact on China’s pharmaceutical sector.